All In Biotech

BLA 761079 · Biomarin Pharm

Palynziq

Pegvaliase-Pqpz · Injection · Phenylalanine Metabolizing Enzyme

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

May 24, 2018

Approved uses

5

Original approval plus efficacy supplements

Registered trials

11

4 Phase 3, 5 recruiting

FAERS reports

8,518

1,340 serious, 12 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ANAPHYLAXIS Anaphylaxis has been reported after administration of PALYNZIQ and may occur at any time during treatment [see Warnings and Precautions (5.1) ] . Administer the initial dose of PALYNZIQ under the supervision of a healthcare provider equipped to manage anaphylaxis, and closely observe patients for at least 60 minutes following injection. Prior to self-injection, confirm patient competency with self-administration, and patient's and observer's (if applicable) ability to recognize signs and symptoms of anaphylaxis and administer epinephrine, if needed [see Dosage and Administration (2.5) ] . Consider having an adult observer for patients who may need assistance in recognizing and managing anaphylaxis during PALYNZIQ treatment. If an adult observer is needed, the observer should be present during and for at least 60 minutes after PALYNZIQ administration, should be able...

What it is approved for

From the label in effect Mar 2, 2026.

PALYNZIQ is indicated to reduce blood phenylalanine concentrations in adult and pediatric patients 12 years of age and older with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management. PALYNZIQ is a phenylalanine (Phe)-metabolizing enzyme indicated to reduce blood phenylalanine concentrations in adult and pediatric patients 12 years of age and older with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management. ( 1 )

Mechanism: Pegvaliase-pqpz is a PEGylated phenylalanine ammonia lyase (PAL) enzyme that converts phenylalanine to ammonia and trans -cinnamic acid. It substitutes for the deficient phenylalanine hydroxylase (PAH) enzyme activity in patients with PKU and reduces blood phenylalanine concentrations.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 27, 2026 Supplement 31 · Efficacy · priority review OrphanLetterLabel
  • Oct 6, 2020 Supplement 6 · Efficacy OrphanLetter
  • Oct 6, 2020 Supplement 7 · Efficacy OrphanLetter
  • Oct 6, 2020 Supplement 5 · Efficacy OrphanLetterLabel
  • May 24, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
3 products under this application
  • PALYNZIQ · PEGVALIASE-PQPZ 20MG/ML · INJECTABLE, INJECTION · Prescription
  • PALYNZIQ · PEGVALIASE-PQPZ 2.5MG/0.5ML · INJECTABLE, INJECTION · Prescription
  • PALYNZIQ · PEGVALIASE-PQPZ 10MG/0.5ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pegvaliase" as an intervention, any sponsor and status, largest first.

All 11 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • arthralgia1,463
  • injection site reaction957
  • injection site erythema794
  • injection site swelling584
  • rash533
  • urticaria523
  • headache461
  • injection site pain448
  • injection site pruritus389
  • fatigue386
  • pruritus359
  • hypersensitivity357

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2018156
20191,038
20201,207
20211,114
2022860
20231,027
20241,148
20251,082
2026886

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Palynziq (PEGvaliase-Pqpz)

2024 spending

$24.7M

Beneficiaries

109

958 claims

Per beneficiary

$226,254

$796.02 per unit

View as table
YearSpending
2020$11,917,017
2021$15,293,515
2022$15,703,046
2023$20,307,239
2024$24,661,658

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 14 on PubMed

Sponsor: BioMarin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.